drugset / Trial / NCT05043987
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
Non-randomizedSequentialOpen-labelTreatment
Summary
This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion study conducted in patients with advanced late stage cancer (pancreatic or gastric including esophageal junction cancers) for which the investigator determines there to be no other standard of care or higher priority therapies available.
Timeline
- Start
- 2022-11-16
- Primary completion
- 2022-11-16
- Completion
- 2022-11-16
Outcome
Outcome not reported
Stopped: “New IND sponsor to initiate a separate study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPO102 | Unknown | 0.5 mg/kg | Intravenous |
| Subject | CPO102 | Unknown | 1 mg/kg | Intravenous |
| Subject | CPO102 | Unknown | 1.8 mg/kg | Intravenous |
| Subject | CPO102 | Unknown | 2.5 mg/kg | Intravenous |
| Subject | CPO102 | Unknown | 3.5 mg/kg | Intravenous |
| Subject | CPO102 | Unknown | 4.5 mg/kg | Intravenous |
| Subject | CPO102 | Unknown | 5.5 mg/kg | Intravenous |